Table 3: Treatment and clinical outcome.
|
Total patients n = 51 |
n (%) |
|
Treatment |
|
|
Antiviral therapy |
19 (37) |
|
Lopinavir/Ritonavir (Kaletra) |
12 (63) |
|
Ribavirin |
7 (37) |
|
Hydroxychloroquine |
46 (90) |
|
Azithromycin |
44 (86) |
|
Broad spectrum antibiotics |
24 (47) |
|
Tocilizumab (IL-6* receptor blocker) |
5 (10) |
|
Intravenous immunoglobulin therapy |
1 (2) |
|
Intensive care unit (ICU) transfer |
7 (14) |
|
Oxygen therapy |
4(57) |
|
Invasive ventilation |
3(43) |
|
ECMO** |
0 (0) |
|
Clinical outcome |
|
|
Cured |
35 (69%) |
|
Death |
2 (4%) |
|
inpatient |
14 (27%) |
|
ICU |
0 (0) |
Sum of decimals have been rounded to whole number where appropriate
*Interleukin-6, **Extracorporeal membrane oxygenation.